VWM
EW icon

Vermillion Wealth Management’s Edwards Lifesciences EW Stock Holding History

Vermillion Wealth Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33
Closed -$2.64K – 1831
2026
Q1 		$2.64K Buy
+33
New +$2.72K ﹤0.01% 603

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Vermillion Wealth Management's EW Position: Q2 2026 in Review

Vermillion Wealth Management sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 33 shares — an estimated $2.64K sold.

Vermillion Wealth Management first reported a position in EW in Q1 2026 and held it in 1 quarter. The position peaked at $2.64K in Q1 2026. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Vermillion Wealth Management reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
  • Vermillion Wealth Management sold 33 Edwards Lifesciences shares in Q2 2026, an estimated $2.64K.
  • Vermillion Wealth Management first reported a position in Edwards Lifesciences in Q1 2026 and held it in 1 quarter.
  • Vermillion Wealth Management's Edwards Lifesciences position peaked at $2.64K in Q1 2026.
  • 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.